Alzheimer disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• APOE 16
• MAPT 2
• APP 1
• NRF2 0
• NLRP3 0
• TREM2 0
• AKT 0
• BDNF 0
• TDP-43 2
• PI3K 0
• BACE1 0
• GLP-1 1
• MAPK 0
• PPAR 0
• AMPK 0
• mTOR 0
• PSEN1 1
• STING 0
• ERK 0
• NMDA 1
• SNCA 0
• TLR4 0
• JNK 0
• SIRT1 0
• CTNNB1 0
• STAT3 0
• TP53 0
• TNF 0
• HDAC 0
• HIF-1 0
• SGLT2 0
• HMGB1 0
• GPX4 0
• IL-1 0
• PCSK9 0
• COX-2 0
• HSP90 1
• C9orf72 0
• DPP-4 0
• PINK1 0
• IL-17 0
• TFEB 0
• IL-6 0
• PD-L1 0
• VEGF 0
• YAP 0
• AQP4 0
• CD33 0
• IGF1R 0
• MMP-9 0
• CCR5 0
• EGFR 0
• FTO 0
• GBA1 0
• GIP 0
• JAK 0
• KEAP1 0
• PARP 0
• PD-1 0
• ACE2 0

3 of 3+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIMH · F31

  The role of the default mode network in representing and remembering mental states

  Boston College· Chestnut Hill, United States· US$35,733 awarded in fiscal year 2026· until Oct 2028

• U.S. Department of Veterans Affairs · I01

  SleepSMART for Veterans with Insomnia and Mild Cognitive Impairment: A Randomized Clinical Trial

  Va San Diego Healthcare System· San Diego, United States· until Sept 2031

• U.S. Department of Veterans Affairs · IK2

  Cognitive Risk Profiles Among Aging Veterans: Harnessing Big Data for Precision Medicine

  Va San Diego Healthcare System· San Diego, United States· until Sept 2031

• NIH NIA · R03

  Improve and Validate Amyloid Pathology Visualization and Analysis in Intact Brain Samples

  Massachusetts General Hospital· Boston, United States· US$329,220 awarded in fiscal year 2026· until Sept 2028

• NIH NIA · R01

  Enhanced Mapping of Alzheimer's Disease Risk Loci Using Multimodal RNAseq Data

  Emory University· Atlanta, United States· US$653,912 awarded in fiscal year 2026· until May 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Neuroinflammation and Virus Imaging for Smart Therapeutic Approaches (NEUROVISTA)

  Umea Universitet· Umea, Sweden· EU contribution €236,340· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Interneuron subtype-specific control of hippocampal memory encoding and retrieval (INSPIRE)

  Universitaetsklinikum Freiburg· Freiburg, Germany· EU contribution €202,125· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Warfare and Agricultural Resilience Nexus in the Ancient Mediterranean (6th. BC - 4th c. AD) (WARNex)

  University College Dublin, National University of Ireland, Dublin· Dublin, Ireland· EU contribution €252,729· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Attentional Control and Mapping in Spatial Navigation: Defining Behavioral Fingerprints for Early Alzheimer’s Risk Detection (SPATIALOS)

  Universitat Jaume I de Castellon· Castellon De La Plana, Spain· EU contribution €209,915· until Apr 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Principles of UFMylation-driven antibacterial defence (UBACT)

  Universite de Geneve· Geneve, Switzerland· EU contribution €1,898,233· until Apr 2032

  The disease is named only in the funder's project summary, not in the title.

10 of 5,135 running projects, newest first. Listed amounts together: US$4.3bn + €321.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 86
• Organoids 36
• Mendelian Randomization Analysis 136
• CRISPR-Cas Systems 24
• Gene Expression Profiling 176
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 17
• Exome Sequencing 7
• Proteomics 229
• Metabolomics 81
• Mass Spectrometry 62
• Flow Cytometry 16
• Immunohistochemistry 74
• Liquid Biopsy 5
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 676
• Magnetic Resonance Imaging 1001
• Machine Learning 253
• Deep Learning 166
• Cohort Studies 536
• Genome-Wide Association Study 216

• Systematic Dissection of Key Driver Perturbation Signatures in Single Cells via ECCITE-seq.

  Methods Mol Biol, Jan 2027

• scMINA: an interpretable workflow for paired scRNA-scATAC multiome integration and regulatory prioritization.

  NAR Genom Bioinform, Nov 2026

• Single-cell machine learning uncovers genetically anchored, cell-type specific programs of Alzheimer's disease.

  Nat Commun, Nov 2026

• Single-cell, spatial, and machine learning analyses identify ANKIB1 as an oligodendrocyte-anchored palmitoylation-associated candidate biomarker of Alzheimer's disease.

  Transl Psychiatry, Oct 2026

• Bisphenol A Exposure Perturbs the Immune Microenvironment in Alzheimer's Disease: Insights from Network Toxicology and Single-Cell Transcriptomics.

  J Mol Neurosci, Oct 2026

• Integrating Morphology and Gene Expression of Neural Cells in Unpaired Single-Cell Data Using GeoAdvAE.

  J Comput Biol, Sept 2026

• Spatial cell-cell communication inference based on cell-spot-ligand-receptor heterogeneous graphs.

  PLoS Comput Biol, Sept 2026

• Efficient differential expression analysis of large-scale single-cell transcriptomics data using Dreamlet.

  Nat Commun, Sept 2026

• Personalized single-cell transcriptomics reveals molecular diversity in Alzheimer's disease.

  Nat Commun, Sept 2026

• AI-based characterization of Alzheimer's disease phenotypes from population-scale single-cell data.

  Nat Med, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.